Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 211 entries
View as:

First Human Trial of Targeting MDM2/MDMX PET Imaging

Phase: N/A Priority: Normal
NCT ID: NCT06443762 Org: User:
Start: 01/03/25 End: 05/23/25 Due: 05/23/26

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Phase: N/A Priority: Normal
NCT ID: NCT06991790 Org: User:
Start: 05/01/25 End: 05/01/28 Due: 05/01/29

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04264936 Org: User:
Start: 02/15/20 End: 12/31/21 Due: 12/31/22

The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04542837 Org: User:
Start: 09/11/20 End: 03/15/24 Due: 03/15/25

Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02867839 Org: User:
Start: 04/24/17 End: 09/01/21 Due: 09/01/22

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06443671 Org: User:
Start: 06/01/24 End: 06/01/28 Due: 06/01/29

Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05656144 Org: User:
Start: 02/28/23 End: 06/30/25 Due: 06/30/26

Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04296240 Org: User:
Start: 03/01/19 End: 04/30/24 Due: 04/30/25

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Phase: N/A Priority: Normal
NCT ID: NCT06099821 Org: User:
Start: 10/25/23 End: 12/31/26 Due: 12/31/27

Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03425058 Org: User:
Start: 11/22/17 End: 10/01/21 Due: 10/01/22

Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC

Phase: N/A Priority: Normal
NCT ID: NCT03708783 Org: User:
Start: 07/01/18 End: 12/30/23 Due: 12/30/24

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Phase: N/A Priority: Normal
NCT ID: NCT06360042 Org: User:
Start: 01/01/24 End: 03/31/28 Due: 03/31/29

Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT03031444 Org: User:
Start: 01/31/16 End: 12/30/20 Due: 12/30/21

Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)

Phase: N/A Priority: Normal
NCT ID: NCT03199989 Org: User:
Start: 06/01/17 End: 07/31/24 Due: 07/31/25

Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection

Phase: N/A Priority: Normal
NCT ID: NCT02767375 Org: User:
Start: 02/28/15 End: 12/31/18 Due: 12/31/19

Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)

Phase: N/A Priority: Normal
NCT ID: NCT01180153 Org: User:
Start: 08/31/10 End: 08/31/12 Due: 08/31/13

Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02724176 Org: User:
Start: 01/31/12 End: 01/31/16 Due: 01/31/17

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05380024 Org: User:
Start: 08/17/22 End: 06/30/24 Due: 06/30/25

Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)

Phase: N/A Priority: Normal
NCT ID: NCT01231022 Org: User:
Start: 08/31/10 End: 06/30/13 Due: 06/30/14

Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06306755 Org: User:
Start: 06/25/24 End: 12/31/34 Due: 12/31/35

Preliminary Study on Eye Features of Patients With Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04224298 Org: User:
Start: 02/01/19 End: 09/20/22 Due: 09/20/23

Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy

Phase: N/A Priority: Normal
NCT ID: NCT03613142 Org: User:
Start: 01/01/19 End: 12/30/21 Due: 12/30/22

Drug Sensitivity Screening for Gastrointestinal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04298489 Org: User:
Start: 05/01/17 End: 04/30/22 Due: 04/30/23

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions

Phase: N/A Priority: Normal
NCT ID: NCT06648317 Org: User:
Start: 11/21/24 End: 12/01/25 Due: 12/01/26

Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02330783 Org: User:
Start: 12/31/14 End: 12/31/18 Due: 12/31/19